LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To monitor treatment with heparin or other blood-thinning medications (anticoagulants) when undergoing heart bypass surgery, coronary angioplasty, or dialysis
When you are receiving high doses of heparin to prevent clotting during surgical procedures such as a heart bypass; when heparin levels are too high to allow monitoring with a PTT and/or when a rapid result is necessary to monitor treatment
A blood sample drawn from a vein in your arm
The activated clotting time (ACT) is a test that is used primarily to monitor high doses of unfractionated (standard) heparin therapy. Heparin is a drug that inhibits blood clotting (anticoagulant) and is usually given intravenously (IV) by injection or continuous infusion. High doses of heparin may be given during procedures that require that blood be prevented from clotting, such as heart bypass surgery.
In moderate doses, heparin is used to help prevent and treat inappropriate blood clot formation (thrombosis or thromboembolism) and is monitored using the partial thromboplastin time (PTT) or the heparin antifactor Xa test. Monitoring is a vital part of the anticoagulation therapy because a particular quantity of heparin can affect each person a little bit differently. If the amount of heparin administered is insufficient to inhibit the body's clotting system, blood clots may form in blood vessels throughout the body. If there is too much heparin, the patient may experience excessive, even life-threatening, bleeding.
High doses of heparin are given, for example, before, during, and for a short time after, open heart surgeries. During these operations, the patient's heart and lungs are often bypassed. Their blood is filtered and oxygenated outside of the body using mechanical devices. The blood's contact with artificial surfaces activates platelets and coagulation, initiating a sequence of steps that results in blood clot formation. A high dose of heparin prevents clot formation but leaves the body in a delicate dynamic balance between clotting and bleeding. At this level of anticoagulation, the PTT is no longer clinically useful as a monitoring tool. The PTT test involves an in vitro clotting reaction and at high levels of heparin, it will not clot. In these cases, the ACT must be used for monitoring.
The activated clotting time (ACT) is commonly used to monitor treatment with high-dose heparin before, during, and shortly after medical procedures that require that blood be prevented from clotting, such as heart bypass surgery, cardiac angioplasty, and dialysis.
High doses of heparin are given before, during, and for a short time after, some medical procedures that require extracorporeal life support (ECLS). During these procedures, the patient's blood is filtered and oxygenated outside of the body using mechanical devices. The blood's contact with artificial surfaces activates the clotting process. Special cell fragments in the blood called platelets and proteins called coagulation factors are activated in a sequence of steps that results in blood clot formation. A high dose of heparin prevents clot from forming during ECLS but results in a delicate balance between clotting and bleeding.
The ACT is a rapid test that can be performed at a person's bedside prior to surgery or other medical procedures and in or near the operating room at intervals during and immediately after surgery. (This type of testing is known as point-of-care testing.) ACT testing allows relatively rapid changes in heparin infusion, helping to achieve and maintain a constant level of anticoagulation. Once the procedure is complete and the patient has been stabilized, heparin doses are typically decreased.
The ACT measures the inhibiting effect that heparin has on the body's clotting system, not the actual level of heparin in the blood. The sensitivity of the ACT test to heparin depends on the method used. Some ACT tests are designed to monitor lower levels of heparin while others are best at monitoring high levels of heparin. When heparin reaches therapeutic maintenance levels, the ACT is usually replaced as a monitoring tool by the PTT.
The ACT test is also sometimes used to monitor regular-dose heparin therapy in people with documented lupus anticoagulant (LAC). The PTT test cannot be used in those patients because LAC interferes with the PTT. In rare clinical situations, the ACT test may also be used to monitor the inhibiting effect of a different class of anticoagulation drugs called direct thrombin inhibitors (e.g., argatroban) on the clotting system.
The ACT is ordered after someone has received an initial dose (bolus) of heparin and before the start of an open heart surgery or other procedure that requires a high level of anticoagulation. During surgery, the ACT is measured at intervals to achieve and maintain a steady level of heparin anticoagulation. After surgery, the ACT is monitored until the person has stabilized and the heparin dosage has been reduced and/or neutralized with a counter agent.
Occasionally, the ACT may be measured during a bleeding episode or used as part of a bedside evaluation of a person's heparin anticoagulation level, particularly if the person has lupus anticoagulant.
It may also be used when someone is receiving direct thrombin inhibitor therapy.
The ACT is measured in seconds: the longer the time to clot, the higher the degree of clotting inhibition. During surgery, the ACT is kept above a lower time limit, a limit at which most people will not form blood clots. There is no widespread agreement of exactly what this lower limit should be. It will vary from hospital to hospital and depends to some degree on the method used to determine ACT.
It is important to evaluate how the person is responding to this ACT lower limit and to the amount of heparin that person is being given. The amount of heparin needed to reach and maintain a certain ACT (for instance, 300 seconds) will vary as will the body's clotting potential at that ACT. If there are clotting or bleeding problems, the dosages and ACT may need to be adjusted accordingly. After surgery, the ACT may be maintained within a narrow range (for instance, 175 - 225 seconds) until the person has stabilized.
ACT and PTT results are not interchangeable. In the area where they overlap (upper measurements of PTT and lower levels of ACT), they have poor correlation. ACT and PTT results should be evaluated independently. It is better to determine someone's heparin anticoagulant requirements, stabilize the person, and then change the monitoring tool.
The ACT may be influenced by a person's platelet count and platelet function. Platelets that are activated during surgery often become dysfunctional, and both surgery and heparin can sometimes cause platelet numbers to decrease (thrombocytopenia). The temperature of the blood may also affect ACT results; the blood tends to cool during surgery as it is mechanically filtered and oxygenated. Acquired and inherited conditions such as coagulation factor deficiencies may also affect ACT results.
Rarely is the test performed in the central laboratory. The sample is not stable and the result is needed rapidly to guide treatment. So the test must be performed immediately, close to the patient, usually at the person's bedside, in the operating room, or in a laboratory close to these locations. The ACT is therefore considered a point-of-care test.
The ACT test is generally not affected by lupus anticoagulant (LAC). Nevertheless, the presence of LAC has been shown to interfere with certain ACT testing. Therefore, it is important for the laboratory to follow the manufacturer's instructions and determine if the test is suitable to monitor heparin therapy in a person with documented history of LAC or antiphospholipid syndrome.
Sources Used in Current Review
Pagana, K. D., Pagana, T. J., and Pagana, T. N. (© 2015). Mosby's Diagnostic & Laboratory Test Reference 12th Edition: Mosby, Inc., Saint Louis, MO. Pp 9-10.
Kostousov, V. (Updated 2014 January 15). Activated Clotting Time. Medscape Drugs & Diseases [On-line information]. Available online at http://emedicine.medscape.com/article/2084818-overview. Accessed on 8/29/15.
Achneck, H. et. al. (2010). Contemporary Reviews in Cardiovascular Medicine, Pathophysiology of Bleeding and Clotting in the Cardiac Surgery Patient From Vascular Endothelium to Circulatory Assist Device Surface. Circulation. 2010; 122: 2068-2077 [On-line information]. Available online at http://circ.ahajournals.org/content/122/20/2068.full. Accessed on 8/29/15.
(2012 April 29 Updated). Activated Clotting Time [ACT]. Practical-Haemostasis.com. [On-line information]. Available online at http://practical-haemostasis.com/Miscellaneous/Miscellaneous%20Tests/act.html. Accessed on 8/29/15.
Sources Used in Previous Reviews
Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 9-11.
Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry, AACC Press, Washington, DC. Pg 233.
Wu, A. (2006). Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders Elsevier, St. Louis, Missouri. Pp 44-46.
Ganter, M. et. al. (2005). Monitoring Activated Clotting Time for Combined Heparin and Aprotinin Application: An In Vitro Evaluation of a New Aprotinin-Insensitive Test Using SONOCLOT. Anesth Analg 2005; 101:308-314. [On-line journal article]. Available online through http://www.anesthesia-analgesia.org. Accessed on 8/18/07.
(2007 May 29). Activated Clotting Time. Massachusetts General Hospital Pathology Service [On-line information]. Available online through http://www.massgeneral.org/pathology. Accessed on 8/12/07.
Baird, C. et. al. (2007). Anticoagulation and Pediatric Extracorporeal Membrane Oxygenation: Impact of Activated Clotting Time and Heparin Dose on Survival. Ann Thorac Surg 2007;83:912-920. [On-line journal article]. Available online through http://ats.ctsnetjournals.org. Accessed on 8/18/07.
Jabr K, Johnson JH, McDonald MH, Walsh DL, Martin WD, Johnson AC, Pickett JM, Shantha-Martin U. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technol. 2004; 36:174-7.
Tremey B, Szekely B, Schlumberger S, François D, Liu N, Sievert K, Fischler M. Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR). Br J Anaesth. 2006; 97:453-9.
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
(2002 November 19, Updated). Activated Clotting Time. Mass. Gen Hospital, Pathology Service, Laboratory Medicine Coag Test Handbook Index [On-line information]. Available online through http://www.mgh.harvard.edu.
Carville, D. and Guyer, K. (2000 September). Hemostasis testing: Past, present, and future. Medical devicelink [On-line information]. Available online through http://www.devicelink.com.
(1998 Spring). Anticoagulation Services Newsletter. Detroit Medical Center Department of Pharmacy Services, v 3 (2) [On-line Newsletter]. PDF available for download at http://www.dmcpharmacy.org.
Chapter 2: Mediastinal Bleeding / Emergency Sternotomy, Manipulations on Cardiopulmonary Bypass. Stony Brook State Univ of NY, Dept of Surgery, Cardiac Surgical Residents Handbook.
Zwischenberger, J. and Bartlett, R. What is ECLS? An Introduction to Extracorporeal Life Support. University of Michigan Health System [On-line information]. Available online through http://www.med.umich.edu.
Menta, S. (1999 Spring). The Coagulation Cascade. Physiology Disorders Evaluation, College of Medicine, Univ of Florida.
Elstrom, R. (2001 November 25, Updated). PTT. MedlinePlus Health Information, Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003653.htm.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 10-12.
Pagnani, G. et. al. (Updated 2009 May 29). Massachusetts General Hospital Activated Clotting Time performed on the Medtronic ACT PlusTM. Massachusetts General Hospital. [On-line information]. PDF available for download at http://www.massgeneral.org/pathology/assets/poct/MGH-Medtronic-ACT-Plus-procedure.pdf. Accessed July 2011.
Calkins et al. (2007 June) Catheter and Surgical Ablation of AF. Society of Thoracic Surgeons, Heart Rhythm, Vol 4, No 6 [On-line information]. PDF available for download at http://www.sts.org/sites/default/files/documents/pdf/guidelines/HR_Afib_Ablation.pdf. Accessed July 2011.
Marmur, J. et al. (2010 March 8). Avoiding Intelligence Failures in the Cardiac Catheterization Laboratory: Strategies for the Safe and Rational Use of Dalteparin or Enoxaparin during Percutaneous Coronary Intervention. Medscape Today from J Invasive Cardiol. 2009;21(12):653-64 [On-line information]. Available online at http://www.medscape.com/viewarticle/715597. Accessed July 2011.
Ganter M, Hofer C. Coagulation Monitoring: Current Techniques and Clinical Use of Viscoelastic Point-of-Care Coagulation Devices. Anesthesia & Analgesia May 2008 vol. 106 no. 5, Pp 1366-1375. Available online at http://www.anesthesia-analgesia.org/content/106/5/1366.long. Accessed August 2011.